# Monitoring JE Antibody Levels in Healthy Populations and Immunization Strategy in Low-Prevalence Areas

> **NCT06678373** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Liaoning Chengda Biotechnology CO., LTD** · enrollment: 250 (estimated)

## Conditions studied

- Japanese Encephalitis

## Interventions

- **BIOLOGICAL:** Liaoning Chengda Inactivated Japanese Encephalitis Vaccine
- **BIOLOGICAL:** Liaoning Chengda Inactivated Japanese Encephalitis Vaccine
- **BIOLOGICAL:** Liaoning Chengda Inactivated Japanese Encephalitis Vaccine

## Key facts

- **NCT ID:** NCT06678373
- **Lead sponsor:** Liaoning Chengda Biotechnology CO., LTD
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-11-14
- **Primary completion:** 2026-04-30
- **Final completion:** 2026-12-31
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2024-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06678373

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06678373, "Monitoring JE Antibody Levels in Healthy Populations and Immunization Strategy in Low-Prevalence Areas". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT06678373. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*